A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
NCT01000311
Completed
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
Gender:
ALL
Ages:
Between 55 days and 89 days
Trial Updated:
04/03/2014
Locations: 25 Center for Pharmaceutical Research 1010 Carondelet Drive Suite 426, Kansas City, Missouri
Conditions: Meningococcal Disease
Register for Updates
Influenza Vaccine Revaccination in Ambulatory Elderly Subjects
NCT00775450
Completed
This is a multi-center study designed to evaluate the safety and immunogenicity of a Fluzone revaccination in elderly adults aged ≥ 65 years. Primary Objective: To describe the safety profile for all subjects. Secondary Objective: To describe immunogenicity 28 days following revaccination with one of three Fluzone formulations.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
12/05/2013
Locations: Not set, Kansas City, Missouri +2 locations
Conditions: Influenza, Orthomyxovirus Infection, Myxovirus Infection
Register for Updates
Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery
NCT00006470
Completed
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining these two treatments may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining vaccine therapy with radiation therapy in treating patients who have stage II or stage IIIA non-small cell lung cancer that has been completely removed in surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/09/2013
Locations: Ellis Fischel Cancer Center - Columbia, Columbia, Missouri +5 locations
Conditions: Lung Cancer
Register for Updates
Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003386
Terminated
RATIONALE: Vaccines made from tumor tissue may make the body build an immune response and kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy in treating patients who have stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/10/2013
Locations: CCOP - Kansas City, Kansas City, Missouri +1 locations
Conditions: Ovarian Cancer
Register for Updates
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
NCT00845429
Completed
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects. Secondary Objective: To describe the safety following a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
12/13/2012
Locations: Not set, Kansas City, Missouri +1 locations
Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Register for Updates
S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
NCT00045617
Terminated
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells. Vaccines may make the body build an immune response to kill tumor cells. Combining chemotherapy and radiation therapy with vaccine therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy and radiation therapy with vaccine therapy in treating patients who hav... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/11/2012
Locations: Veterans Affairs Medical Center - Kansas City, Kansas City, Missouri +4 locations
Conditions: Lung Cancer
Register for Updates
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™
NCT00772928
Completed
This study is designed to evaluate in a controlled manner the effect of Prevnar® on the immune responses of Pentacel™ Primary Objective - Stage I: To compare the immune responses elicited by an infant series of Pentacel™ when given at different times from or concurrently with a Pneumococcal conjugate vaccine (Prevnar®). Primary Objective - Stage II: To compare the immune responses elicited by a 4th dose of Pentacel™ when given at different times from or concurrently with Prevnar®.
Gender:
ALL
Ages:
Between 42 days and 89 days
Trial Updated:
01/30/2012
Locations: Not set, Kansas City, Missouri
Conditions: Diphtheria, Tetanus, Haemophilus Infection, Pertussis, Polio
Register for Updates
Double Blind, Safety and Immunogenicity Study of Recombinant Botulinum Vaccine A/B
NCT00764634
Completed
This Phase 2 study is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B-40 vaccine or placebo in healthy adults, using two different three-dose dosing schedules.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
11/28/2011
Locations: Center for Pharmaceutical Research, Kansas City, Missouri
Conditions: Botulism Vaccine
Register for Updates
Study Comparing Immune Response to, and Safety of, Fluviral and Fluzone Influenza Vaccines in Persons 50 y.o. and Over
NCT00232947
Completed
The goal of this study is to determine whether the immune responses induced by Fluviral, the investigational vaccine, are comparable to those induced by Fluzone, which is an influenza vaccine currently licensed in the U.S. The study focuses on persons 50 years old and over. In addition, the study will compare the rate of reactions to the two vaccines, and the general health of persons who receive them over the 42 days after immunization.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
01/19/2007
Locations: The Center for Pharmaceutical Research, Kansas City, Missouri
Conditions: Influenza
Register for Updates